Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain [8,53,74,75,76].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been suggested that this association may account for the earlier onset of symptoms in E4 carriers (21–23).”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Young, cognitively normal apoE4 carriers have glucose hypometabolism in brain regions affected by AD [29–31]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests the possibility that an apoE-related decrease in brain metabolism may contribute to development of AD (Reiman et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, studies looking at both young and old non-demented carriers of the apoE4 isoform observed a similar regional pattern of hypometabolism prior to the onset of disease that correlates with the changes seen in the AD brain.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Spatial registration and normalization of images
Friston, K. J., Ashburner, J., Frith, C. D., Poline, J. ‐., Heather, J. D., & Frackowiak, R. S. J. (1995) · Human Brain Mapping · doi:10.1002/hbm.460030303 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929
Research works printed but not linked: 3
- Rogers, S. L. & Friedhoff, L. T. (1996) Dementia 7, 293-303.
- Huang, S. C., Phelps, M. E., Hoffman, E. J., Sideris, K., Selin, C. J. & Kuhl, D. E. (1980) Am. J. Physiol. 238, E69-82.
- Benton, A. L. (1974) The Revised Visual Retention Test (Psychological Corp., New York).
Cited by
Items 401–500 of 796
Beal, M. F. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05575.x · Cited by 41
Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders
McDonald, T. S., Lerskiatiphanich, T., Woodruff, T. M., McCombe, P., & Lee, J. D. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221135061 · Cited by 36
“An expanding body of evidence also suggests that insulin abnormalities and insulin resistance contribute to AD pathophysiology.101 Higher plasma insulin concentrations and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) scores in healthy middle-aged people were shown to predict cognitive decline and incr…”
BackgroundInfluentialZhang, Q., Yu, J., Wang, P., Chen, W., Wu, Z., Jiang, H. F., & Tan, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.10.074 · Cited by 39
“First, there is reduced metabolism of oxygen and glucose in the brain of AD patients (Orth and Schapira, 2001), especially in the areas that are known to be affected early in AD (Small et al., 2000).”
BackgroundExploiting Common Aspects of Obesity and Alzheimer’s Disease
Tabassum, S., Misrani, A., & Yang, L. (2020) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.602360 · Cited by 36
Housekeepers for accurate transcript expression analysis in Alzheimer's disease autopsy brain tissue
Gebhardt, F. M., Scott, H. A., & Dodd, P. R. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.11.002 · Cited by 36
“For example, cerebral glucose metabolism is correlated with the severity of dementia in AD [9], whereas a link between altered insulin transduction and AD has been proposed [10].”
BackgroundImaging Phenotypes and Genotypes in Schizophrenia
Turner, J. A., Smyth, P., Macciardi, F. M., Fallon, J. H., Kennedy, J. L., & Potkin, S. G. (2006) · Neuroinformatics · doi:10.1385/ni:4:1:21 · Cited by 39
“02_Potkin 1/13/06 12:02 PM Page 35 Neuroinformatics_________________________________________________________________ Volume 4, 2006 (e.g., Bookheimer et al., 2000; Small et al., 2000; Small, 2002).”
Iqbal, J., Zhang, K., Jin, N., Zhao, Y., Liu, Q., Ni, J., & Shen, L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00034 · Cited by 36
A Brief History of Voxel-Based Grey Matter Analysis in Alzheimer's Disease
Diaz-de-Grenu, L. Z., Acosta‐Cabronero, J., Chong, Y. F. V., Pereira, J., Sajjadi, S. A., Williams, G. B., & Nestor, P. J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130362 · Cited by 35
“A diaschisis hypothesis—often also referred to as a “disconnection” hypothesis—has been proposed to reconcile the findings of structural and metabolic data [19, 45–51].”
ResultJagust, W. J., Koeppe, R. A., Rabinovici, G. D., Villemagne, V. L., Harrison, T. M., Landau, S. M., & Initiative, T. A. D. N. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14165 · Cited by 34
O'Dwyer, L., Lamberton, F., Matura, S., Scheibe, M., Miller, J., Rujescu, D., Prvulovic, D., & Hampel, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036024 · Cited by 34
Moulin‐Romsee, G., Maes, A., Silverman, D., Mortelmans, L., & Van Laere, K. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00940.x · Cited by 32
“Especially in view of the literature pointing towards the fact that PET can predict the rate of future decline based on cerebral metabolism (Small et al., 2000), it also diminishes the frustrations of equivocal or additional diagnostic test results.”
BackgroundSelf-citationObject naming and semantic fluency among individuals with genetic risk for Alzheimer's disease
Miller, K. J., Rogers, S. A., Siddarth, P., & Small, G. W. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1262 · Cited by 35
“It is these regions that also show hypometabolism and decreased synaptic activity among those who carry the APOE-4 allele (Small et al., 1995; Small et al., 2000; Silverman et al., 1999).”
BackgroundSelf-citationMatthews, B. R., Siemers, E., & Mozley, P. D. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00005 · Cited by 36
O'Hara, R., Luzon, A., Hubbard, J., & Zeitzer, J. M. (2009) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2008.10.0140 · Cited by 31
“These same hippocampal regions, which subserve delayed recall, also appear vulnerable to deleterious effects of the APOE ε4 allele [77–79].”
BackgroundMatura, S., Prvulovic, D., Butz, M., Hartmann, D., Sepanski, B., Linnemann, K., Oertel‐Knöchel, V., Karakaya, T., Fußer, F., Pantel, J., et al. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12659 · Cited by 32
Diagnostic Issues in Dementia: Neuroimaging as a Surrogate Marker of Disease
Small, G. W. (2006) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706291089 · Cited by 33
“9 to detect a 1-unit decline from baseline to follow-up using a 1-tailed test.(31) A sample size of only 20 participants, therefore, would be needed in each treatment arm (ie, active drug or placebo) to detect a drug effect size of .”
MethodSelf-citationFluoro-2-Deoxy-D-Glucose (FDG)-PET in APOEε4 Carriers in the Australian Population
Rimajova, M., Lenzo, N. P., Wu, J.-S., Bates, K. A., Campbell, A., Dhaliwal, S. S., McCarthy, M., Rodrigues, M., Paton, A., Rowe, C., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13203 · Cited by 28
“Furthermore, a number of studies have also demonstrated an AD-like pattern of region-specific glucose hypometabolism in APOE ε 4 carrying individuals [9, 17,53,62,63,65,71,73,74].”
Scorer, C. A. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02042-6 · Cited by 36
Ercoli, L., Siddarth, P., Huang, S.-C., Miller, K., Bookheimer, S. Y., Wright, B. C., Phelps, M. E., & Small, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.442 · Cited by 31
“The procedure has been previously described.(32) Be-”
BackgroundSelf-citationChildren of Persons With Alzheimer Disease: What Does the Future Hold?
Jarvik, L. F., LaRue, A. A., Blacker, D., Gatz, M., Kawas, C. H., McArdle, J. J., Morris, J. C., Mortimer, J. A., Ringman, J. M., Ercoli, L. M., et al. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653ac · Cited by 33
Self-citationPerspective on a pathogenesis and treatment of Alzheimer's disease
Roses, A. D., & Saunders, A. M. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.12.001 · Cited by 34
Self-citationAPOE and metabolic dysfunction in Alzheimer's disease
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.002 · Cited by 31
β-hydroxybutyrate is a metabolic regulator of proteostasis in the aged and Alzheimer disease brain
Madhavan, S. S., Diaz, S. R., Peralta, S., Nomura, M., King, C. D., Ceyhan, K. E., Lin, A., Bhaumik, D., Foulger, A., Shah, S., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.11.001 · Cited by 33
Peretti, D. E., García, D. V., Reesink, F. E., Doorduin, J., de Jong, B. M., Deyn, P. P. D., Dierckx, R. A. J. O., & Boellaard, R. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0528-3 · Cited by 30
Suthana, N., Krupa, A. K., Donix, M., Burggren, A. C., Ekstrom, A. D., Jones, M., Ercoli, L. M., Miller, K. J., Siddarth, P., Small, G. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.12.014 · Cited by 33
Self-citationChételat, G., Desgranges, B., & Eustache, F. (2006) · Revue Neurologique · doi:10.1016/s0035-3787(06)75104-9 · Cited by 36
Brain metabolic differences between sporadic and familial Alzheimer’s disease
Mosconi, L., Sorbi, S., Nacmias, B., Cristofaro, M. T. D., Fayyaz, M., Cellini, E., Bagnoli, S., Bracco, L., Herholz, K., & Pupi, A. (2003) · Neurology · doi:10.1212/01.wnl.0000086816.30011.75 · Cited by 31
Patterson, J. C., Lilien, D. L., Takalkar, A. M., & Pinkston, J. B. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2011/946590 · Cited by 30
Potashkin, J. A., Bottero, V., Santiago, J. A., & Quinn, J. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222921 · Cited by 31
“The PCC shows a reduction in glucose metabolism in early AD and has the largest abnormal positron emission tomography scans of cognitively normal late-middle age individuals who carry the APOE epsilon 4 allele [24, 38, 39].”
BackgroundRole of Mitochondrial Dysfunction in the Pathology of Amyloid-β
Huang, Z., Yan, Q., Wang, Y., Zou, Q., Li, J., Liu, Z., & Cai, Z. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200519 · Cited by 32
Jin, M., Pelak, V. S., Curran, T., Nandy, R. R., & Cordes, D. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2011.12.014 · Cited by 30
“N IH -PA Author M anuscript N IH -PA Author M anuscript impairment or MCI) but does not meet criteria for dementia usually precedes the diagnosis of AD and other dementias (Small et al., 2000; Palmer et al., 2003).”
BackgroundSun, Z., Zhu, Y. ‐., Liu, H., Liu, J., Zhu, X. ‐., Zhou, J., & Liu, R. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01579.x · Cited by 33
“Moreover, nondemented subjects with apoE e4 allele also showed cortical metabolic rate decline [33].”
BackgroundParietal cortex activation predicts memory decline in apolipoprotein E-εε4 carriers
Lind, J., Ingvar, M., Persson, J., Sleegers, K., Van Broeckhoven, C., Adolfsson, R., Nilsson, L.-G., & Nyberg, L. (2006) · NeuroReport · doi:10.1097/01.wnr.0000239954.60695.c6 · Cited by 27
“Support for this notion was reported by Small and colleagues [7].”
BackgroundResultPharmacogenomics in cardiovascular diseases
Mukherjee, D., & Topol, E. J. (2002) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2002.123467 · Cited by 38
The search for antecedent biomarkers of Alzheimer's disease
Fagan, A. M., Csernansky, C. A., Morris, J. C., & Holtzman, D. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8404 · Cited by 30
“In addition, lower base-line performance was found to predict future cognitive decline [118].”
Longitudinal Functional Alterations in Asymptomatic Women at Risk for Alzheimer's Disease
Smith, C. D., Kryscio, R. J., Schmitt, F. A., Lovell, M. A., Blonder, L. X., Rayens, W. S., & Andersen, A. H. (2005) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2005.tb00321.x · Cited by 30
Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease
Rapoport, S. I. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120178897 · Cited by 29
Regional Cerebral Glucose Metabolism in Monozygotic Twins Discordant for Alzheimer’s Disease
Järvenpää, T., Räihä, I. J., Kaprio, J. A., Koskenvuo, M. J., Laine, M., Kurki, T. J. I., Vahlberg, T. J., Viljanen, T., Ahonen, K., & Rinne, J. O. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000072809 · Cited by 31
Foster, N. L., Wang, A. Y., Taşdizen, T., Fletcher, P. T., Hoffman, J. M., & Koeppe, R. A. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.10.004 · Cited by 32
PET is better than perfusion SPECT for early diagnosis of Alzheimer’s disease
Ishii, K., & Minoshima, S. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1936-3 · Cited by 29
Reiman, E. M., Caselli, R. J., Alexander, G. E., & Chen, K. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(01)00006-8 · Cited by 28
Kaneko, K., Kuwabara, Y., Sasaki, M., Ogomori, K., Ichimiya, A., Koga, H., Nakagawa, M., Hayashi, K., & Honda, H. (2004) · Clinical Nuclear Medicine · doi:10.1097/01.rlu.0000127091.43180.92 · Cited by 27
“In addition, in APOE-4 carriers, a left posterior cingulate metabolic rate decline of 4%, despite no change in memory performance scores, has been shown to be indicative of a metabolic decline that began before clinical deterioration was apparent.(23) According to a previous report,(6,7) metabolic reduction in the tem…”
ResultUddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Barreto, G. E., BUNGAU, S. G., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02065-3 · Cited by 28
Affuso, F., Micillo, F., & Fazio, S. (2024) · Biomedicines · doi:10.3390/biomedicines12081888 · Cited by 26
“It leads to neuronal death, particularly in the hippocampus, cortex and temporal and parietal lobes, regions primarily affected by the disease [66–69].”
BackgroundAlzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 30
Song, H., Long, H., Zuo, X., Yu, C., Liu, B., Wang, Z., Wang, Q., Wang, F., Han, Y., & Jia, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133179 · Cited by 26
Functional connectivity between right and left mesial temporal structures
Lacuey, N., Zonjy, B., Kahriman, E. S., Kaffashi, F., Miller, J. P., & Lüders, H. O. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0810-0 · Cited by 26
“It supports the assertion that the hippocampus is connected to the posterior cingulate gyrus (Small et al. 2000).”
Mitochondria-Targeted Molecules as Potential Drugs to Treat Patients With Alzheimer's Disease
Reddy, A. P., & Reddy, P. H. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.12.010 · Cited by 31
Astroglial contribution to tau-dependent neurodegeneration
Sidoryk‐Wȩgrzynowicz, M., & Strużyńska, L. (2019) · Biochemical Journal · doi:10.1042/bcj20190506 · Cited by 26
Role of biomarkers in studies of presymptomatic Alzheimer's disease
Morris, J. C., Kimberly, A., Quaid, K. A., Holtzman, D. M., Kantarci, K., Kaye, J. A., Reiman, E. M., Klunk, W. E., & Siemers, E. (2005) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.09.013 · Cited by 26
Neuroimaging and Human Genetics
Winterer, G., Hariri, A. R., Goldman, D. A., & Weinberger, D. R. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(05)67010-9 · Cited by 26
Animal Models of Alzheimer’s Disease
Newman, M., Kretzschmar, D., Khan, I., Chen, M., Verdile, G., & Lardelli, M. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00040-1 · Cited by 31
Enhanced temporal complexity of EEG signals in older individuals with high cognitive functions
Iinuma, Y., Nobukawa, S., Mizukami, K., Kawaguchi, M., Higashima, M., Tanaka, Y., Yamanishi, T., & Takahashi, T. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.878495 · Cited by 25
“Furthermore, the temporal and parietal lobes showed the greatest reduction in brain glucose metabolism, associated with cognitive decline in patients with AD (Small et al., 2000).”
BackgroundSchreiner, S. J., Kirchner, T., Wyss, M., Bergen, J. M. G. V., Quevenco, F. C., Steininger, S. C., Griffith, E. Y., Meier, I. B., Michels, L., Gietl, A. F., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.022 · Cited by 26
“…cognitively normal elderly subjects has been linked to increased risk for sporadic Alzheimer’s disease (AD) (Elias et al., 2000; Grober et al., 2000; Linn et al., 1995; Pasquier, 1999; Small et al., 2000a) and may reflect preclinical brain change (Albert et al., 2011; Caselli et al., 2007).”
BackgroundRosen, A. C., Bokde, A. L. W., Pearl, A., & Yesavage, J. A. (2002) · Brain and Cognition · doi:10.1016/s0278-2626(02)00520-1 · Cited by 27
Cerebral blood volume in Alzheimer's disease and correlation with tissue structural integrity
Uh, J., Lewis‐Amezcua, K., Martin‐Cook, K., Cheng, Y., Weiner, M., Diaz-Arrastia, R. R., Devous, M. D., Shen, D. G., & Lu, H. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.12.010 · Cited by 26
Bartrés‐Faz, D., Serra-Grabulosa, J. M., Sun, F. T., Solé‐Padullés, C., Rami, L., Molinuevo, J. L., Bosch, B., Mercader, J. M., Bargalló, N., Falcón, C., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.021 · Cited by 29
Imaging neurochemical endophenotypes: promises and pitfalls
Martínez, D., Broft, A. I., & Laruelle, M. A. (2001) · Pharmacogenomics · doi:10.1517/14622416.2.3.223 · Cited by 28
Rogojin, A., Gorbet, D. J., Hawkins, K. M., & Sergio, L. E. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190403 · Cited by 25
“Specifically,imagingstud-ieshavedemonstratedreductionsinbrainglucose uptake,changesinbrainlipidmetabolism,lossof blood-brainbarrierintegrity,anddecreasedcerebral bloodflow[81–83].”
Apolipoprotein E Genotype and Early Alzheimer's Disease: A Longitudinal SPECT Study
Sakamoto, S., Matsuda, H., Asada, T., Ohnishi, T., Nakano, S., Kanetaka, H., & Takasaki, M. (2003) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2003.tb00167.x · Cited by 24
“These rCMRglu reductions in the posterior cingulate gyrus and precuneus have been reported in presymptomatic, nondemented individualss who were cognitively normal and had at least a single ε4 allele.(32,33) The relation between the ε4 allele and the progression rate of AD has been controversial from the standpoint of…”
BackgroundInfluence of APOE Genotype on Whole-Brain Functional Networks in Cognitively Normal Elderly
Seo, E. H., Lee, D. Y., Lee, J. M., Park, J.-S., Sohn, B. K., Choe, Y. M., Byun, M. S., Choi, H. J., & Woo, J. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083205 · Cited by 27
“In the current study, ε4+ CN elderly showed hypermetabolism in the frontal and temporal regions, as well as hypometabolism in the bilateral cuneus, while previous FDGPET studies assessing the effect of ε4 gene in CN elderly reported only hypometabolism in the brain regions similar to the AD-affected areas [17,49].”
ResultApolipoprotein E Related Co-Morbidities and Alzheimer’s Disease
Singhrao, S. K., Harding, A., Chukkapalli, S. S., Olsen, I., Kesavalu, L. N., & Crean, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad150690 · Cited by 26
“The individuals having inherited the heterozygous or homozygous apoε4 allelic variant metabolise glucose at a lower rate than those with apoε2 and apoε3 [85]; and the inflammatory mediators contribute to insulin resistance and disturbance in lipid and glucose metabolism [79].”
BackgroundInsulin resistance: an emerging link in Alzheimer’s disease
Medhi, B., & Chakrabarty, M. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1454-1 · Cited by 24
“reduction in the regional cerebral metabolic rate of glucose has been reported to exist in AD brain [36].”
BackgroundPokryszko‐Dragan, A., Bladowska, J., Zimny, A., Słotwiński, K., Zagrajek, M., Gruszka, E., Bilińska, M. M., Sąsiadek, M. J., & Podemski, R. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.01.013 · Cited by 24
“We deliberately chose for analysis the parietal region and the posterior cingulate gyrus (a part of the limbic system, functionally connected with the medial temporal lobe, hippocampal formation and thalamus) as the areas which correspond best with cognitive performance in MRS studies in healthy persons [23] as well a…”
MethodResultCurrent Status of 18F-FDG PET Brain Imaging in Patients with Dementia
Sarikaya, İ., Sarıkaya, A., & Elgazzar, A. H. (2018) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.118.210237 · Cited by 25
“18F-FDG PET/CT is commonly used in the early and differential diagnosis of subtypes of dementias (6,7).”
Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer’s disease
Small, G. W. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00151-5 · Cited by 27
Self-citationDevelopment of Alzheimer's disease imaging agents for clinical studies
Ryu, E. K., & Chen, X. (2007) · Frontiers in bioscience · doi:10.2741/2719 · Cited by 23
“For example, apolipoprotein E (ApoE) is well known as a genetic risk factor for AD (113-115).”
BackgroundApoE genotype and abnormal auditory cortical potentials in healthy older females
Irimajiri, R., Golob, E. J., & Starr, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.09.005 · Cited by 24
Mitochondrial Regulatory Pathways in the Pathogenesis of Alzheimer’s Disease
Adiele, R. C., & Adiele, C. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150967 · Cited by 23
“It has been postulated that reduction of neuronal energy status precedes and sometimes coincides with onset of cognitive deficit in AD following or in association with reduced glucose uptake and utilization in brain areas known to be involved in memory processing [43–45].”
MMSE Items Predict Cognitive Decline in Persons with Genetic Risk for Alzheimer's Disease
Ercoli, L. M., Siddarth, P., Dunkin, J. J., Bramen, J. E., & Small, G. W. (2003) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988703016002001 · Cited by 28
“Subjects The 78 nondemented subjects were drawn from 2 larger longitudinal studies of predictors of cognitive decline.(18,25) Eight subjects in the present analyses participated in both studies, but their data were used only once, based on the earliest time point at which they had a complete data set.”
MethodSelf-citationSridharan, B., & Lee, M. (2021) · Current Molecular Medicine · doi:10.2174/1566524021666211004104703 · Cited by 27
Alzheimer’s disease: an axonal injury disease?
Liang, D., & Zhang, Z. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1264448 · Cited by 23
Positron Emission Tomography Imaging in Dementia
Herholz, K. (2008) · European Neurological Review · doi:10.17925/enr.2008.03.02.109 · Cited by 22
Neuroimaging Through the Course of Alzheimer's Disease
Smith, C. D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1217 · Cited by 23
“Decreased PET resting glucose metabolism in posterior cingulate and parietal cortex has been demonstrated in normal subjects at increased risk of early-onset AD due to presenilin [166] or amyloid-β protein precursor (AβPP) mutations [167], and in subjects with a family history of late-onset AD and at least one APOE4 a…”
Translational NeuroImaging of the CNS: Novel Pathways to Drug Development
Fox, G. B., Chin, C.-L., Luo, F. R., Day, M., & Cox, B. F. (2009) · Molecular Interventions · doi:10.1124/mi.9.6.6 · Cited by 23
Neill, D. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.06.004 · Cited by 25
Kulasingam, S., Samsa, G. P., Zarin, D. A., Rutschmann, O., Patwardhan, M. B., McCrory, D. C., Schmechel, D. E., & Matchar, D. B. (2003) · Value in Health · doi:10.1046/j.1524-4733.2003.65248.x · Cited by 22
Apostolova, L. G., Thompson, P. M., Rogers, S., Dinov, I. D., Zoumalan, C., Steiner, C. A., Siu, E., Green, A. E., Small, G. W., Toga, A. W., et al. (2009) · Molecular Imaging and Biology · doi:10.1007/s11307-009-0247-7 · Cited by 24
Self-citationExpanding ventricles may detect preclinical Alzheimer disease
Weiner, M. W. (2008) · Neurology · doi:10.1212/01.wnl.0000304743.72127.cc · Cited by 21
Triebswetter, C., Kiely, M., Khattar, N., Ferrucci, L., Resnick, S. M., Spencer, R. G. S., & Bouhrara, M. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.118988 · Cited by 22
“Furthermore, the APOE ε4 allele has been associated with decreased metabolism in several brain structures, which has been shown to predict cognitive decline after 2 years of longitudinal follow-up (79).”
BackgroundYang, J. J. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-01907-2 · Cited by 21
Effect of Apolipoprotein E Genotype on Cerebral Autoregulation During Cardiopulmonary Bypass
Ti, L. K., Mathew, J. P., Mackensen, G. B., Grocott, H. P., White, W. D., Reves, J. G., & Newman, M. F. (2001) · Stroke · doi:10.1161/01.str.32.7.1514 · Cited by 22
Westlye, E. T., Hodneland, E., Haász, J., Espeseth, T., Lundervold, A., & Lundervold, A. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.06.072 · Cited by 23
“Furthermore, the strong, positive relationship between EWM FA and memory performance, driven by APOE ε4 carriers, should be interpreted in the context of the increased vulnerability for memory decline and AD in this APOE group extensively reported in previous studies (Corder et al., 1993; Deary et al., 2002; Roses, 19…”
BackgroundHyperpolarized [1-13C]lactate flux increased in the hippocampal region in diabetic mice
Choi, Y.-S., Song, J. E., Lee, J., Kim, E., Kim, C., Kim, D.-H., & Song, H.-T. (2019) · Molecular Brain · doi:10.1186/s13041-019-0505-9 · Cited by 18
Children of Alzheimer Patients: An Overview
Jarvik, L. F., & Blazer, D. G. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705281859 · Cited by 21
How Available is Positron Emission Tomography in the United States?
Patterson, J. C., & Mosley, M. (2005) · Molecular Imaging and Biology · doi:10.1007/s11307-005-4116-8 · Cited by 21
Pupi, A., Mosconi, L., Nobili, F. M., & Sorbi, S. (2004) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0953-8 · Cited by 23
“FDGPET studies showed that cognitively unimpaired individuals carrying the APOE E4 allele demonstrate abnormally low baseline metabolism within the posterior cingulate, parietal, and temporal cortex, which was predictive of memory decline after two years [36, 37].”
BackgroundResultChapter 4 Functional neuroimaging of cognition
Perani, D. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)88004-3 · Cited by 21
Ketone esters increase brown fat in mice and overcome insulin resistance in other tissues in the rat
Veech, R. L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12222 · Cited by 20
Stonnington, C. M., Velgos, S. N., Chen, Y., Syed, S., Huentelman, M. J., Thiyyagura, P., Lee, W., Richholt, R., Caselli, R. J., Locke, D. E. C., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200132 · Cited by 18
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac111.74687492 · Cited by 29
Blass, J. P., & Gibson, G. E. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9212 · Cited by 18
“In AD, the first detectable decreases in brain metabolism precede detectable loss of brain substance (by MRI) or any neuropsychologicalabnormalities [25, 26].”
Cha, H., Choi, J. H., Jeon, H., Kim, J. H., Kim, M., Kim, S. J., Park, W., Lim, J. S., Lee, E., Ahn, J. S., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03475-9 · Cited by 17
NSAIDs may protect against age-related brain atrophy
Bendlin, B. B., Newman, L. M., Ries, M. L., Puglielli, L., Carlsson, C. M., Sager, M. A., Rowley, H. A., Gallagher, C. L., Willette, A. A., Alexander, A. L., et al. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00035 · Cited by 19
The Molecular Basis of Disease
Barrio, J. R. (2004) · Springer eBooks · doi:10.1007/978-0-387-22529-6_4 · Cited by 17
Self-citationNordberg, A. K. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)45021-8 · Cited by 17
Pharmacogenomics in cardiovascular diseases
Mukherjee, D., & Topol, E. J. (2003) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2003.09.002 · Cited by 17
Affective Disorders and Alzheimer Disease: A Missing-Link Hypothesis
Rasgon, N., Jarvik, G. P., & Jarvik, L. F. (2001) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00015 · Cited by 16
Self-citationThe Role of Mitochondrial Genes in Neurodegenerative Disorders
Kumar, R., Harilal, S., Parambi, D. G. T., Kanthlal, S. K., Rahman, M. A., Alexiou, A. T., Batiha, G. E., & Mathew, B. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210908163839 · Cited by 16
“In AD, mosaic respiratory anomalies are seen in cortical neurons, a scenario identical to PD [89, 90] along with cerebral energy hypometabolism [91, 92].”
Boundy, K. L., Barnden, L. R., Katsifis, A. G., & Rowe, C. C. (2005) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2004.06.012 · Cited by 16
Metadata
- Authors
- Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., & Phelps, M. E.
- Affiliations
- University of California, Los Angeles (US)
- Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024; Departments of Molecular and Medical Pharmacology and Neurology, and Brain Mapping Center, University of California, Los Angeles, CA 90095; Department of Medicine, Duke University Medical Center, Durham, NC 27710; and Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-05-16
- Volume
- 97
- Issue
- 11
- Pages
- 6037-6042
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18554
- OpenAlex
- W2164303459
- Cited by
- 790
- References
- 53
- Citations by year
- 2026: 13 · 2025: 8 · 2024: 12 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 20 · 2018: 17 · 2017: 22 · 2016: 17 · 2015: 14 · 2014: 27 · 2013: 34 · 2012: 30
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy
- Alzheimer's Association
- Ahmanson Foundation
- National Institutes of Health (AG10123, MH52453, NS26630)
- U.S. Public Health Service
- National Institute on Aging (AG-13308, P50AG016570, P50AG005128, R01AG013308, P60AG011268, P30AG010123, U24AG021886)
- National Institute of Mental Health (MH52453, R01MH052453)
- National Institute of Neurological Disorders and Stroke (P01NS026630, R01NS031153)
- National Center for Research Resources (M01RR000865)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, APOE ε4, genetic risk, brain glucose metabolism, cognitive decline, posterior cingulate cortex, inferior parietal cortex, lateral temporal cortex, preclinical Alzheimer's disease, memory performance, non-demented elderly, longitudinal follow-up
- MeSH terms
- Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Brain, Cognition Disorders, Female, Follow-Up Studies, Genotype, Humans, Male, Memory Disorders, Middle Aged, Psychological Tests, Risk Factors, Tomography, Emission-Computed, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.